KDM4 抑制剂的最新进展及潜在应用
Recent Advances with KDM4 Inhibitors and Potential Applications.
机构信息
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
出版信息
J Med Chem. 2022 Jul 28;65(14):9564-9579. doi: 10.1021/acs.jmedchem.2c00680. Epub 2022 Jul 15.
Abstract
The histone lysine demethylase 4 (KDM4) family plays an important role in regulating gene transcription, DNA repair, and metabolism. The dysregulation of KDM4 functions is associated with many human disorders, including cancer, obesity, and cardiovascular diseases. Selective and potent KDM4 inhibitors may help not only to understand the role of KDM4 in these disorders but also to provide potential therapeutic opportunities. Here, we provide an overview of the field and discuss current status, challenges, and opportunities lying ahead in the development of KDM4-based anticancer therapeutics.
摘要
组蛋白赖氨酸去甲基酶 4（KDM4）家族在调节基因转录、DNA 修复和代谢方面发挥着重要作用。KDM4 功能的失调与许多人类疾病有关，包括癌症、肥胖和心血管疾病。选择性和有效的 KDM4 抑制剂不仅有助于了解 KDM4 在这些疾病中的作用，而且还为提供潜在的治疗机会。在这里，我们提供了该领域的概述，并讨论了在开发基于 KDM4 的抗癌治疗方法方面的当前现状、挑战和机遇。
相似文献
1
Recent Advances with KDM4 Inhibitors and Potential Applications.KDM4 抑制剂的最新进展及潜在应用
J Med Chem. 2022 Jul 28;65(14):9564-9579. doi: 10.1021/acs.jmedchem.2c00680. Epub 2022 Jul 15.
2
KDM4 Demethylases: Structure, Function, and Inhibitors.KDM4去甲基化酶：结构、功能及抑制剂
Adv Exp Med Biol. 2023;1433:87-111. doi: 10.1007/978-3-031-38176-8_5.
3
Advances in histone demethylase KDM4 as cancer therapeutic targets.组蛋白去甲基酶 KDM4 的研究进展及其作为癌症治疗靶点的潜力。
FASEB J. 2020 Mar;34(3):3461-3484. doi: 10.1096/fj.201902584R. Epub 2020 Jan 21.
4
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.TACH101，一种首创的组蛋白去甲基化酶 KDM4 泛抑制剂。
Anticancer Drugs. 2023 Nov 1;34(10):1122-1131. doi: 10.1097/CAD.0000000000001514. Epub 2023 Mar 24.
5
Unravelling KDM4 histone demethylase inhibitors for cancer therapy.解析 KDM4 组蛋白去甲基化酶抑制剂在癌症治疗中的作用。
Drug Discov Today. 2021 Aug;26(8):1841-1856. doi: 10.1016/j.drudis.2021.05.015. Epub 2021 May 26.
6
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.组蛋白赖氨酸去甲基化酶KDM4和KDM5家族的细胞穿透抑制剂。1. 3-氨基-4-吡啶羧酸衍生物。
J Med Chem. 2016 Feb 25;59(4):1357-69. doi: 10.1021/acs.jmedchem.5b01537. Epub 2016 Jan 15.
7
KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.用于抗癌药物的KDM4组蛋白去甲基化酶抑制剂：专利综述
Expert Opin Ther Pat. 2015 Feb;25(2):135-44. doi: 10.1517/13543776.2014.991310. Epub 2014 Dec 3.
8
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.组蛋白赖氨酸去甲基化酶KDM4和KDM5家族的细胞穿透抑制剂。2. 吡啶并[3,4-d]嘧啶-4(3H)-酮衍生物。
J Med Chem. 2016 Feb 25;59(4):1370-87. doi: 10.1021/acs.jmedchem.5b01538. Epub 2016 Jan 15.
9
Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.鉴定一种新型苯并咪唑吡唑酮支架，该支架可抑制 KDM4 赖氨酸去甲基酶并减少前列腺癌细胞的增殖。
SLAS Discov. 2017 Aug;22(7):801-812. doi: 10.1177/2472555217699157. Epub 2017 Mar 27.
10
Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.组蛋白去甲基化酶KDM4C的底物和辅因子非依赖性抑制
ACS Chem Biol. 2014 Sep 19;9(9):2131-8. doi: 10.1021/cb500374f. Epub 2014 Jul 17.
引用本文的文献
1
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics.通过高通量蛋白质组学对cereblon新底物图谱进行无偏映射。
Nat Commun. 2025 Aug 20;16(1):7773. doi: 10.1038/s41467-025-62829-0.
2
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach.表观遗传编辑与表观遗传药物：一种同时靶向KDM4的联合策略，作为一种新型抗癌方法。
Clin Epigenetics. 2025 Jun 19;17(1):105. doi: 10.1186/s13148-025-01913-0.
3
Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.肺泡横纹肌肉瘤的分子靶点：进展与陷阱的叙述性综述
Int J Mol Sci. 2025 May 28;26(11):5204. doi: 10.3390/ijms26115204.
4
Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors.探索吡啶羧酸异构体发现新型酶抑制剂的潜力。
Drug Des Devel Ther. 2025 May 20;19:4039-4091. doi: 10.2147/DDDT.S513461. eCollection 2025.
5
Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase.临床使用的低氧诱导因子脯氨酰羟化酶抑制剂地西司他的衍生物是人类γ-丁甜菜碱羟化酶的有效抑制剂。
J Med Chem. 2025 May 8;68(9):9777-9798. doi: 10.1021/acs.jmedchem.5c00586. Epub 2025 Apr 22.
6
KDM4C works in concert with GATA1 to regulate heme metabolism in head and neck squamous cell carcinoma.KDM4C与GATA1协同作用，调节头颈部鳞状细胞癌中的血红素代谢。
Cell Mol Life Sci. 2025 Apr 21;82(1):170. doi: 10.1007/s00018-025-05693-x.
7
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers.异染色质保真度是淋巴瘤和其他人类癌症中的一种治疗易损性。
bioRxiv. 2025 Feb 5:2025.01.31.635709. doi: 10.1101/2025.01.31.635709.
8
Bio-nanocomplexes impair iron homeostasis to induce non-canonical ferroptosis in cancer cells.生物纳米复合物破坏铁稳态，从而在癌细胞中诱导非经典铁死亡。
J Nanobiotechnology. 2025 Feb 19;23(1):121. doi: 10.1186/s12951-025-03117-3.
9
Epigenetics-targeted drugs: current paradigms and future challenges.表观遗传学靶向药物：当前范例与未来挑战。
Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
10
Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery.靶向癌症中的N-甲基赖氨酸组蛋白去甲基化酶KDM4：天然产物抑制剂作为表观遗传药物发现的驱动力
ChemMedChem. 2025 Feb 16;20(4):e202400682. doi: 10.1002/cmdc.202400682. Epub 2024 Nov 21.
本文引用的文献
1
Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor.用Jumonji家族组蛋白去甲基化酶抑制剂使耐药乳腺癌细胞致敏
Cancers (Basel). 2022 May 26;14(11):2631. doi: 10.3390/cancers14112631.
2
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.PD-1 阻断在错配修复缺陷、局部晚期直肠癌中的应用。
N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.
3
JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.JIB-04 具有广谱抗病毒活性，能够抑制 SARS-CoV-2 复制和冠状病毒发病机制。
mBio. 2022 Feb 22;13(1):e0337721. doi: 10.1128/mbio.03377-21. Epub 2022 Jan 18.
4
Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.治疗性干扰生殖细胞肿瘤的表观遗传景观：比较药物研究和新的机制见解。
Clin Epigenetics. 2022 Jan 7;14(1):5. doi: 10.1186/s13148-021-01223-1.
5
Screening for Active Compounds Targeting Human Natural Killer Cell Activation Identifying Daphnetin as an Enhancer for IFN-γ Production and Direct Cytotoxicity.筛选靶向人自然杀伤细胞激活的活性化合物，鉴定瑞香素为 IFN-γ 产生和直接细胞毒性的增强剂。
Front Immunol. 2021 Dec 8;12:680611. doi: 10.3389/fimmu.2021.680611. eCollection 2021.
6
Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survival.抑制 Jumonji 去甲基化酶可重新编程严重扩张型心肌病并延长生存期。
J Biol Chem. 2022 Feb;298(2):101515. doi: 10.1016/j.jbc.2021.101515. Epub 2021 Dec 18.
7
Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer.一种苯并咪唑苄基吡唑赖氨酸去甲基化酶抑制剂的增强特性：作用机制、结合位点分析及在前列腺癌细胞模型中的活性
J Med Chem. 2021 Oct 14;64(19):14266-14282. doi: 10.1021/acs.jmedchem.1c00693. Epub 2021 Sep 23.
8
A protocol for high-throughput screening of histone lysine demethylase 4 inhibitors using TR-FRET assay.一种使用时间分辨荧光共振能量转移（TR-FRET）测定法进行组蛋白赖氨酸去甲基酶 4 抑制剂高通量筛选的方案。
STAR Protoc. 2021 Aug 26;2(3):100702. doi: 10.1016/j.xpro.2021.100702. eCollection 2021 Sep 17.
9
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.靶向 KDM4B 以激活 c-Myc 调节的代谢，抑制去势抵抗性前列腺癌的肿瘤生长。
Theranostics. 2021 Jun 26;11(16):7779-7796. doi: 10.7150/thno.58729. eCollection 2021.
10
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.发现一种有效的、选择性的组蛋白赖氨酸去甲基化酶 KDM4D 的抑制剂。
Eur J Med Chem. 2021 Nov 5;223:113662. doi: 10.1016/j.ejmech.2021.113662. Epub 2021 Jun 26.
Zotero 插件